CClinicalTrials.gg
CompletedNCT02189265Updated Jul 14, 2014

Assessing the Impact of Smoke-free Legislation on Perinatal Health in the Netherlands

An observational study in Premature Birth, Perinatal Mortality and Infant, Low Birth Weight, sponsored by University of Edinburgh. Completed at 2 sites in 2 countries. Open to participants aged Up to 1 Week, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-14.

Sponsored by University of Edinburgh · Observational

Study type
Observational
Model
Ecologic or community
Time perspective
Retrospective
Enrollment
2,069,695
Ages
Up to 1 Week
Sex
All
01

Study summary

The purpose of this study is to investigate whether there has been a change in perinatal outcomes following the phased smoking ban introduction (January 2004 for workplaces; July 2008 for bars and restaurants) workplaces in the Netherlands.

Read the detailed description

Primary research questions

  1. Is the phased introduction of smoke-free legislation in The Netherlands associated with reductions in adverse perinatal outcomes (e.g. perinatal mortality, preterm birth, small for gestational age)?
  2. How do these associations compare with those described for other European countries in comparable studies (i.e. Belgium (Cox 2013), England (Been et al under review), Scotland (Mackay 2012))?

Study design Retrospective cohort study (using prospective routinely collected health care data)

Study population All singleton births in the Netherlands between January 1st 2000 and December 31st 2011.

Intervention The intervention under study is the ban on smoking in workplaces, and in bars and restaurants implemented in the Netherlands on January 1st, 2004 and July 1st, 2008, respectively.

Inclusion and exclusion criteria We will include all registered singleton births in the Netherlands occurring between January 1st, 2000 and December 31st, 2011. This is the maximum time period surrounding the ban's introduction for which the required birth data are available through the data source. Multiple pregnancies, neonates with chromosomal anomalies, pregnancies with unknown gestational age, pregnancies that ended before 24 weeks and pregnancies resulting in the birth of a child weighing less than 500 grams will be excluded.

Outcome

The primary outcomes are:

  • Perinatal mortality (stillbirth + early neonatal mortality, i.e. within the first 7 days of life)
  • Preterm birth (live birth with gestational age \<37+0 weeks)
  • Small for gestational age (SGA; live birth with birth weight below 10th centile; The Dutch PRN reference curves for birth weight by gestational age according to parity, sex and ethnic background will be used)

To assess whether smoke-free legislation had a selective impact on certain subgroups of outcomes we furthermore identified a number of secondary outcomes:

  • Stillbirth (born dead from 24+0 weeks of gestation)
  • Early neonatal mortality (live birth and death within first 7 days)
  • Very preterm birth (live birth with gestational age \<32+0 weeks)
  • Low birth weight (live birth with birth weight \<2500 grams)
  • Very low birth weight (live birth with birth weight \<1500 grams)
  • Very small for gestational age (live birth with birth weight below percentile 2.3rd centile)
  • Major congenital anomalies (based on reported associations with antenatal smoke exposure (Hackshaw 2011)).

Data sources Individual level health care data will be extracted from The Netherlands Perinatal Registry (PRN). Linked midwifery, obstetric, and neonatal data are available from 2000 to 2011 (including 2011).

Data extraction and handling All relevant variables regarding our outcomes, as well as relevant potential confounders will be extracted from the database.

Sample size Power calculation for interrupted time series modelling is complicated given the complexity of the analysis. Similar previous studies have demonstrated statistically significant and clinically relevant effects of smoke-free legislation on preterm birth (Cox 2013; Mackay 2012; Page 2012), low birth weight (Mackay 2012), SGA (Mackay 2012; Kabir 2013), and perinatal mortality (Mackay et al. and Been et al. both under review). Given the larger population size of the Netherlands as opposed to the regions in which these studies were carried out (except for Been et al. under review), we expect our study to have sufficient power to detect similar effect sizes, should these be present.

Statistical analysis Incidences for each outcome will be presented graphically for each time period to facilitate visualisation of temporal fluctuations and trends in changes of incidence levels. To facilitate timing of the events, date of delivery and expected term date are required for each pregnancy. Data will be presented as outlined in different Tables. Interrupted time series analyses with adjustment for potential confounders will be performed to assess the associations between implementation of smoke-free legislation and primary and secondary outcome measures. Individual-level analysis will be performed using logistic regression analysis. The models will account for the underlying temporal trend in incidence, and will allow for a sudden change in incidence ('step change') following the introduction of the smoking bans. We will test and adjust for any non-linearity in the underlying time trends, and seasonality will be accounted as appropriate.

Sensitivity analyses (primary outcomes only) In recent years, gestational age is usually estimated based on early ultrasonography findings, which is more reliable than estimation based on the last menstrual period. Although the method of ascertainment is not recorded in PRN, there is an item indicating 'certainty' of the gestational age, which is positive in about 93% of records. For the primary outcomes preterm birth and SGA we will perform a sensitivity analysis including only cases in whom gestational age estimation is considered reliable according to this item.

Recent perinatal management changes have been implemented in The Netherlands resulting in increased active management of babies born at the edge of viability (i.e. 23-24 weeks gestation) (NVOG 2010). This has resulted in increased survival at this gestational age as well as altered management of 25-26 week infants, which likely affects the number of babies born preterm (although this effect is expected to be small given the small percentage of all preterm babies being born at this stage), as well as mortality indicators. For the primary outcomes preterm birth and perinatal mortality we will therefore perform a sensitivity analysis excluding babies born before 26 completed weeks of gestation.

Smoking during pregnancy is known to be underreported in the PRN database. Definitions between different caregivers differ; (any) smoking and heavy smoking (>20 cigarettes daily). We will consider performing subgroup analyses of the impact of smoke-free legislation on the primary outcomes according to maternal smoking status during pregnancy.

In a sensitivity analysis we will investigate whether smoke-free legislation has any differential impact on spontaneous preterm birth versus medically indicated preterm birth.

All analyses will be performed using Stata 13.0.

02

Conditions studied

  • Premature Birth
  • Perinatal Mortality
  • Infant, Low Birth Weight
  • Stillbirth
  • Infant Mortality
  • Sudden Infant Death
  • Infant, Very Low Birth Weight
  • Infant, Small for Gestational Age

Keywords

  • Live birth [MeSH]
  • Infant [MeSH]
  • Infant, newborn [MeSH]
  • Second-hand smoke
  • Tobacco smoke pollution [MeSH]
  • Smoke-free
  • Smoke-free policy [MeSH]
03

In context

Premature Birth

2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.

This study's enrollment of 2,069,695 is above the median of 112 across 777 observational studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

University of Edinburgh is the lead sponsor of 393 studies on the registry; 64 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 1 Week
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

All singleton births in the Netherlands. Stillbirths are excluded from the denominator for all outcomes other than stillbirths and congenital anomalies.

Data are obtained via The Netherlands Perinatal Registry (PRN) (6). All registered stillbirths and livebirths occurring in the Netherlands between 1 January 2000 and 31 December 2011 are included.

Inclusion criteria

Inclusion Criteria:

  • Singleton birth occurring in the Netherlands between January 1st, 2000 and December 31st, 2011
  • Liveborn (for all outcomes other than stillbirth and congenital anomalies)

Exclusion criteria

Exclusion Criteria:

  • No chromosomal anomalies
05

Study design

Observational model
Ecologic or community
Time perspective
Retrospective
Enrollment
2,069,695 participants (actual)
Patient registry
No

Groups and cohorts

  • Full cohort

    All singleton births in the Netherlands. Stillbirths are excluded from the denominator for all outcomes other than perinatal mortality, stillbirth and congenital anomalies.

    Other: Smoke-free legislation

Interventions

  • OtherSmoke-free legislation

    The intervention under study is the ban on smoking in workplaces, and in bars and restaurants implemented in the Netherlands on January 1st, 2004 and July 1st, 2008, respectively.

06

What researchers measure

Primary outcomes

  1. Perinatal mortality

    stillbirth (i.e. intrauterine death from 24+0 weeks gestation) or early neonatal mortality (i.e. death within the first 7 days postnatally)

    Time frame: from 24+0 weeks gestation (for stillbirth); up to 7 days postnatally (for early neonatal mortality)

  2. Preterm birth

    live birth with gestational age \>= 24+0 weeks and \<37+0 weeks

    Time frame: gestational age >= 24+0 weeks and <37+0 weeks

  3. Small for gestational age

    live birth at gestational age \>= 24+0 weeks with birth weight below 10th centile

    Time frame: gestational age >= 24+0 weeks

Secondary outcomes

  1. Stillbirth

    born dead from 24+0 weeks of gestation

    Time frame: gestational age >= 24+0 weeks

  2. Early neonatal mortality

    death within first 7 days after live birth at gestational age \>= 24+0 weeks

    Time frame: up to 7 days postnatally after live birth at gestational age >= 24+0 weeks

  3. Very preterm birth

    live birth with gestational age \>= 24+0 weeks and \<32+0 weeks

    Time frame: gestational age >= 24+0 weeks and <32+0 weeks

  4. Low birth weight

    live birth at gestational age \>= 24+0 weeks with birth weight \<2500 grams

    Time frame: gestational age >= 24+0 weeks

  5. Very low birth weight

    live birth at gestational age \>= 24+0 weeks with birth weight \<1500 grams

    Time frame: gestational age >= 24+0 weeks

  6. Very small for gestational age

    live birth at gestational age \>= 24+0 weeks with birth weight below 2.3rd centile

    Time frame: gestational age >= 24+0 weeks

  7. Major congenital anomalies

    birth at \>= 24+0 weeks of gestation with a major birth defect (birth defects known to be influenced by antenatal smoke exposure based on recent systematic review (Hackshaw 2011))

    Time frame: gestational age >= 24+0 weeks

07

Study locations

2 sites
  • Academic Medical Centre
    Amsterdam, Noord Holland, Netherlands
  • Centre for Population Health Sciences, The University of Edinburgh
    Edinburgh, Midlothian EH8 9AG, United Kingdom
08

References and documents

Publications

  • Cox B, Martens E, Nemery B, Vangronsveld J, Nawrot TS. Impact of a stepwise introduction of smoke-free legislation on the rate of preterm births: analysis of routinely collected birth data. BMJ. 2013 Feb 14;346:f441. doi: 10.1136/bmj.f441. PubMed 23412829 ↗
  • Mackay DF, Nelson SM, Haw SJ, Pell JP. Impact of Scotland's smoke-free legislation on pregnancy complications: retrospective cohort study. PLoS Med. 2012;9(3):e1001175. doi: 10.1371/journal.pmed.1001175. Epub 2012 Mar 6. PubMed 22412353 ↗
  • Page RL 2nd, Slejko JF, Libby AM. A citywide smoking ban reduced maternal smoking and risk for preterm births: a Colorado natural experiment. J Womens Health (Larchmt). 2012 Jun;21(6):621-7. doi: 10.1089/jwh.2011.3305. Epub 2012 Mar 8. PubMed 22401497 ↗
  • Kabir Z, Daly S, Clarke V, Keogan S, Clancy L. Smoking ban and small-for-gestational age births in Ireland. PLoS One. 2013;8(3):e57441. doi: 10.1371/journal.pone.0057441. Epub 2013 Mar 26. PubMed 23555561 ↗
  • Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls. Hum Reprod Update. 2011 Sep-Oct;17(5):589-604. doi: 10.1093/humupd/dmr022. Epub 2011 Jul 11. PubMed 21747128 ↗
  • de Laat MW, Wiegerinck MM, Walther FJ, Boluyt N, Mol BW, van der Post JA, van Lith JM, Offringa M; Nederlandse Vereniging voor Kindergeneeskunde; Nederlandse Vereniging voor Obstetrie en Gynaecologie. [Practice guideline 'Perinatal management of extremely preterm delivery']. Ned Tijdschr Geneeskd. 2010;154:A2701. Dutch. PubMed 21429260 ↗
  • Peelen MJ, Sheikh A, Kok M, Hajenius P, Zimmermann LJ, Kramer BW, Hukkelhoven CW, Reiss IK, Mol BW, Been JV. [Tobacco control policies and perinatal health]. Ned Tijdschr Geneeskd. 2017;161:D563. Dutch. PubMed 28120730 ↗
  • Peelen MJ, Sheikh A, Kok M, Hajenius P, Zimmermann LJ, Kramer BW, Hukkelhoven CW, Reiss IK, Mol BW, Been JV. Tobacco control policies and perinatal health: a national quasi-experimental study. Sci Rep. 2016 Apr 22;6:23907. doi: 10.1038/srep23907. PubMed 27103591 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02189265
Lead sponsor
University of Edinburgh
Collaborators
Maastricht University Medical Center, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), The Netherlands Perinatal Registry (PRN)
Responsible party
Jasper Been (Dr., University of Edinburgh) — Principal investigator
First posted
Jul 14, 2014
Start date
Jan 2000
Primary completion
Dec 2011
Completion
Jul 2014
Last update
Jul 14, 2014

Study contacts

Jasper V Been, MD MPH PhD
principal investigator · Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh, Edinburgh, UK

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion